Predict your next investment

Venture Capital
ngncapital.com

See what CB Insights has to offer

Investments

64

Portfolio Exits

13

Funds

2

About NGN Capital

NGN BioMed I, L.P. is a Venture Capital fund dedicated to Healthcare investing, focusing on ventures with the potential to achieve above average private equity returns with an emphasis on later stage investments. The Fund has flexibility to invest in a broad cross section of Healthcare and Biotechnology segments including drug products, medical devices and other healthcare segments like services. The fund is diversified by stage, from later stage to selected early stage opportunities, as well as by geography by investing predominantly in the US and in Europe.

NGN Capital Headquarter Location

369 Lexington Avenue

New York, New York, 10017-6524,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest NGN Capital News

Pershing Square and NGN Capital among 10 firms fined for pay-to-play violations

Jan 17, 2017

News January 17, 2017 —by LeapRate Staff   0 Pinterest The U.S. Securities and Exchange Commission has announced that 10 investment advisory firms have agreed to pay penalties ranging from $35,000 to $100,000 to settle charges that they violated the SEC’s investment adviser pay-to-play rule by receiving compensation from public pension funds within two years after campaign contributions made by the firms’ associates. According to the SEC’s orders, investment advisers are subject to a two-year timeout from providing compensatory advisory services either directly to a government client or through a pooled investment vehicle after political contributions were made to a candidate who could influence the investment adviser selection process for a public pension fund or appoint someone with such influence. The SEC’s orders find that these 10 firms violated the two-year timeout by accepting fees from city or state pension funds after their associates made campaign contributions to elected officials or political candidates with the potential to wield influence over those pension funds. “The two-year timeout is intended to discourage pay-to-play practices in the investment of public money, including public pension funds,” said LeeAnn Ghazil Gaunt, Chief of the SEC Enforcement Division’s Public Finance Abuse Unit. “Advisory firms must be mindful of the restrictions that can arise from campaign contributions made by their associates.” Without admitting or denying the findings, the 10 firms consented to the SEC’s orders finding they violated Section 206(4) of the Investment Advisers Act of 1940 and Rule 206(4)-5. The firms are censured and must pay the following monetary penalties: Adams Capital Management – $45,000

NGN Capital Investments

64 Investments

NGN Capital has made 64 investments. Their latest investment was in Acuamark Diagnostics as part of their Series A on April 4, 2022.

CBI Logo

NGN Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/6/2022

Series A

Acuamark Diagnostics

$11.62M

No

1

3/7/2022

Series F

Cerapedics

$25M

No

2

1/14/2021

Seed VC - II

Humanz AI

$3M

Yes

1

9/25/2019

Seed VC - II

Subscribe to see more

$99M

Subscribe to see more

10

7/6/2018

Series E

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/6/2022

3/7/2022

1/14/2021

9/25/2019

7/6/2018

Round

Series A

Series F

Seed VC - II

Seed VC - II

Series E

Company

Acuamark Diagnostics

Cerapedics

Humanz AI

Subscribe to see more

Subscribe to see more

Amount

$11.62M

$25M

$3M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

2

1

10

10

NGN Capital Portfolio Exits

13 Portfolio Exits

NGN Capital has 13 portfolio exits. Their latest portfolio exit was Suneva Medical on January 12, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/12/2022

Acq - Pending

$99M

1

6/25/2018

Acquired

$99M

2

11/28/2016

Acquired

$99M

7

9/30/2016

IPO

Subscribe to see more

$99M

Subscribe to see more

10

1/9/2014

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/12/2022

6/25/2018

11/28/2016

9/30/2016

1/9/2014

Exit

Acq - Pending

Acquired

Acquired

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

2

7

10

10

NGN Capital Fund History

2 Fund Histories

NGN Capital has 2 funds, including NGN BioMed Opportunity I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

9/30/2005

NGN BioMed Opportunity I

Late-Stage Venture Capital

Closed

$250M

1

NGN BioMed Opportunity II

Subscribe to see more

Subscribe to see more

10

Closing Date

9/30/2005

Fund

NGN BioMed Opportunity I

NGN BioMed Opportunity II

Fund Type

Late-Stage Venture Capital

Subscribe to see more

Status

Closed

Subscribe to see more

Amount

$250M

Sources

1

10

NGN Capital Team

8 Team Members

NGN Capital has 8 team members, including current President, Robert Ausman.

Name

Work History

Title

Status

Georg Nebgen

MPM Capital, Merck & Co., and Roche Holding

Founder

Current

Robert Ausman

President

Current

Leonard Hirsch

Chief Financial Officer

Current

Kenneth S. Abramowitz

Managing General Partner

Current

William J. Gedale

Managing General Partner

Current

Name

Georg Nebgen

Robert Ausman

Leonard Hirsch

Kenneth S. Abramowitz

William J. Gedale

Work History

MPM Capital, Merck & Co., and Roche Holding

Title

Founder

President

Chief Financial Officer

Managing General Partner

Managing General Partner

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.